Taipei Medical University Institutional Repository:Item 987654321/65037
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 45058/58234 (77%)
造访人次 : 2173600      在线人数 : 355
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/65037


    题名: 嗜中性白血球性氣喘中的釋網凋亡
    NETosis in Neutrophilic Asthma
    作者: 林欣樺
    LIN, HSIN-HUA
    贡献者: 醫學科學研究所碩士班
    郭漢彬
    关键词: 嗜中性白血球;氣喘;釋網凋亡
    NETosis;Neutrophil extracellular traps;IL-6;IL-6 trans-signaling;Neutrophilic asthma;Clarithromycin
    日期: 2023-07-21
    上传时间: 2025-01-06 09:24:52 (UTC+8)
    摘要: 氣喘是一個異質性的呼吸道慢性發炎疾病,根據主要參與發炎反應
    的免疫細胞可分為 type 2-high 和 type 2-low 型,其中 type 2-low
    型包含嗜中性球性氣喘,臨床上這類型氣喘的病人通常表現較為嚴
    重的呼吸道症狀,且對於常規氣喘藥物及吸入型類固醇的治療效果
    較差。當嗜中性白血球被活化時可能會釋放出一種網狀結構-嗜中性
    細胞胞外誘捕網,此誘捕網透過細胞毒性酵素的顆粒釋放,破壞病
    原菌的構造與活性而達到免疫目的,先前文獻指出,許多疾病的嚴
    重程度和嗜中性細胞胞外誘捕網有關,例如嗜中性球性氣喘。目前
    的研究已有證據指出白細胞介素-8 會促使嗜中性白血球釋放嗜中性
    細胞胞外誘捕網,但關於白細胞介素-6 是否也會促使嗜中性細胞胞
    外誘捕網的產生,並使得嗜中性球性氣喘病人的呼吸道上皮屏障被
    破壞、症狀加劇,則還不清楚。大環內酯為抗生素的一種,除了作
    為對抗細菌的用藥之外,目前研究指出這類藥品也具有免疫調節的
    功能,可以用來治療一些肺部及呼吸道疾病,用於治療氣喘時則是
    針對非嗜酸性球性氣喘病人效果較佳,且治療後能降低病人體內的
    嗜中性細胞胞外誘捕網含量,然而目前並沒有證據指出嗜中性球性
    氣喘病人使用大環內酯類藥物治療是否能透過減少白細胞介素-6 所
    2
    誘導的嗜中性細胞胞外誘捕網,改善呼吸道上皮屏障的破壞。我們
    的研究結果指出,嚴重型嗜中性球性氣喘病人的痰液內有明顯較高
    的白細胞介素-6 受體、白細胞介素-6 和白細胞介素-8,以及嗜中性
    細胞胞外誘捕網,在使用開羅理黴素 (clarithromycin) 治療過後上述
    物質都有減少的趨勢,且病人的症狀有顯著的改善。我們也證實
    了,白細胞介素-6 確實能使嗜中性白血球釋放嗜中性細胞胞外誘捕
    網,且此誘捕網釋放出來的物質會導致呼吸道上皮細胞的屏障受
    損,而使用開羅理黴素可以抑制此現象發生。因此我們認為嗜中性
    球性氣喘病人使用大環內酯類藥物治療可以透過減少白細胞介素-6
    所誘導的嗜中性細胞胞外誘捕網改善呼吸道上皮屏障的破壞已減緩
    症狀。
    Asthma is a heterogeneous chronic inflammatory respiratory disease.
    According to the immune cells mainly involved in the inflammatory
    response, it can be divided into type 2-high asthma and type 2-low asthma.
    Type 2-low asthma includes neutrophilic asthma. Patients with
    neutrophilic asthma typically present with more severe respiratory
    symptoms and are less responsive to conventional asthma medications and
    inhaled corticosteroids. When neutrophils are activated, they may release
    a web-like structure which called neutrophil extracellular traps (NETs),
    which can destroy the structure and activity of pathogens through the
    release of cytotoxic enzyme particles. Previous researches showed that the
    severity of many diseases is related to NETs, such as neutrophilic asthma.
    Current studies have shown that interleukin (IL)-8 induces the production
    of NETs from neutrophils, but as to whether IL-6 also promotes the
    production of NETs and furthermore cause the epithelial barrier of patients
    with neutrophilic asthma destroyed and the symptoms aggravated is not
    clear. Macrolides are a type of antibiotics. In addition to being used as
    drugs against bacteria, current studies have demonstrated that macrolides
    also have immunomodulatory properties, and can be used to treat some
    4
    lung diseases. When used to treat asthma, they are aimed at patients with
    non-eosinophilic asthma have better outcomes, and the content of NETs of
    those patients can be reduced after treatment. However, there is currently
    no evidence shows that macrolides treatment could recover airway
    epithelial barrier disruption resulted from IL-6-induced NETosis on
    patients with neutrophilic asthma. Our results indicated that the sputum of
    severe neutrophilic asthmatics had significantly higher levels of IL-6
    receptors (IL-6R), IL-6, IL-8, and NETs. These cytokines and NETs tended
    to decrease after treatment with clarithromycin, and the patients’symptoms
    were significantly improved. We also demonstrated that IL-6 can induce
    NETosis, and the NETs caused epithelial disruption, which could be inhibit
    by clarithromycin. Therefore, we speculate that macrolides decrease
    symptoms of severe neutrophilic asthmatics via inhibition of NETosis
    induced by IL-6.
    描述: 碩士
    指導教授:郭漢彬
    口試委員:郭漢彬
    口試委員:李枝新
    口試委員:翁志銘
    附注: 論文公開日期:2024-01-23
    数据类型: thesis
    显示于类别:[醫學科學研究所] 博碩士論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML24检视/开启


    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈